News | December 26, 2007

Medtronic Settles Marquis Defibrillator Lawsuits

December 26, 2007 - Medtronic Inc. announced that it has entered into an agreement to settle lawsuits relating to its Marquis line of implanted cardiac defibrillators that were the subject of a field action announced Feb. 11, 2005, under which it will settle 2,682 cases for $95.6 million plus $18.5 million in attorneys’ fees.

The parties today will file joint requests to the Court for termination of the Multi-District Litigation (MDL) proceedings related to the Marquis devices, as well as requests for dismissal of the cases. The settlement can be terminated by either party if the MDL proceedings are not terminated.

The cases in the settlement are those arising from the February 2005 Marquis device field action, including cases currently filed either in the MDL or in state courts and claims that could have been filed. All settling plaintiffs must satisfy any insurance claims and subrogation interests of Medicare or Medicaid from their settlement payments. No additional sums for these cases will be paid by Medtronic for third-party claims or attorney fees.

The settlement is a compromise of disputed claims, and the parties have not admitted any liability or the validity of any defenses in the litigation.

Medtronic will reflect the Marquis device settlements as a one-time charge in its third fiscal quarter, ending in January 2008.

“We are pleased to settle these cases and put the matter behind us,” said Pat Mackin, senior vice president and president, Medtronic Cardiac Rhythm Disease Management. “We prefer to focus our resources on areas that are beneficial to physicians and patients, rather than prolong this litigation.”

For more information:

Related Content

Boston Scientific Launches Resonate Devices With HeartLogic Heart Failure Diagnostic
Technology | Implantable Cardioverter Defibrillator (ICD)| September 27, 2017
September 27, 2017 — Boston Scientific recently launched the Resonate family of...
Abbott Secures FDA Approval for MRI Compatibility on Ellipse ICD
Technology | Implantable Cardioverter Defibrillator (ICD)| September 22, 2017
Abbott announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for...
Predictive Models May Help Determine Which Patients Benefit From ICDs
News | Implantable Cardioverter Defibrillator (ICD)| July 06, 2017
Two predictive models may help cardiologists decide which patients would most benefit from an implantable cardioverter...
Videos | Implantable Cardioverter Defibrillator (ICD)| June 01, 2017
Lucas Boersma, M.D., Ph.D., FESC, St.
The Unify ICD is one of the SJM devices in an FDA warning letter
Feature | Implantable Cardioverter Defibrillator (ICD)| April 14, 2017 | Dave Fornell
April 14, 2017 — The U.S. Food and Drug Administration (FDA) sent a warning letter to Abbott/St.
ICDs, non-ischemic cardiomyopathy, University of Alabama at Birmingham study, Circulation
News | Implantable Cardioverter Defibrillator (ICD)| January 18, 2017
A new study published in Circulation has found there is a 23 percent risk in reduction of all-cause mortality in non-...
ICDs, implantable cardioverter defibrillators, survival rate, elderly patients, JACC study
News | Implantable Cardioverter Defibrillator (ICD)| January 17, 2017
Of patients over age 65 who received an implantable cardioverter-defibrillator (ICD) after surviving sudden cardiac...
Overlay Init